According to CRI’s market research, after Dulaglutide entered the Chinese market, the sales increased rapidly from CNY0.61 million in 2019 to CNY 10.37million in 2020. The annual growth rate is approximately 1601.52%.

CRI analyzes that the sales of Dulaglutide will keep a growth trend from 2021 to 2025 due to price reduction. At the end of 2020, the negotiation of Dulaglutide medical insurance was successful. The price for 1.5mg/0.5ml Dulaglutide injection was adjusted from CNY420 to CNY149. With the implementation of the latest price, the sales volume of Dulaglutide will increase, which will lead revenue to grow. Besides, the huge patient population will also continue to expand the Dulaglutide market. In China, on average, one in ten adults has diabetes, and 90% of diabetics are Type 2 diabetes. A large number of patients increases the demand for Dulaglutide. Moreover, Dulaglutide is clinically more effective and safer compared to other GLP-1 products. Thus, the share of Dulaglutide expands in the GLP-1 product market, thereby increasing its sales.

Topics Covered:
-The impact of COVID-19 on China’s Dulaglutide market
– Sales value of China’s Dulaglutide 2016-2020
– Competitive landscape of China’s Dulaglutide market
– Prices of Dulaglutide in China
– Prices of Dulaglutide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dulaglutide market
– Prospect of China’s Dulaglutide market from 2021 to 2025

The post Investigation Report on China’s Dulaglutide Market 2021-2025 first appeared on CRI Report.

Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.

Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. By 2020, Janssen Biologics BV is the only manufacturer in the Chinese Infliximab market.

According to CRI’s market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price.

After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.86% in 2020 and reached CNY213.7 million. The CAGR for Infliximab is approximately 14.65% from 2016 to 2020.

CRI analyzes that the sales of Infliximab will keep a growth trend from 2021 to 2025 due to price reduction. After the patent for Infliximab expired, more biosimilar drugs have appeared in the market.

In China, three companies have already submitted applications for Infliximab in 2019 and 2020. Therefore, in the next few years, the market share for Janssen Biologics BV will gradually shrink. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of Infliximab.

Topics Covered:
-The impact of COVID-19 on China’s Infliximab market
– Sales value of China’s Infliximab 2016-2020
– Competitive landscape of China’s Infliximab market
– Prices of Infliximab in China
– Prices of Infliximab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Infliximab market
– Prospect of China’s Infliximab market from 2021 to 2025

Investigation Report on China’s Infliximab Market, 2018-2022

The post Investigation Report on China’s Infliximab Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, after Palbociclib went on the market in China, the sales increased rapidly from CNY298,630 in 2018 to CNY 22.01million in 2019. In 2020, the sales revenue was CNY13.18 million, which decreased 40.12% compared to that in 2019. The main reason is that the COVID-19 epidemic has impacted the overall hospitals’ operation. The CAGR of Palbociclib from 2018 to 2020 is 564.36%.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Palbociclib will have a recovery growth from 2021 to 2025. Besides, the sales will also increase as the market expands. At the end of 2020, Pfizer applied for a new indication for Palbociclib in China. If the new indication is approved, the sales of Palbociclib will increase in the following years. On the other hand, Pfizer announced at the beginning of 2021 that it would reduce the price for Palbociclib by about 54%. Therefore, sales volume in 2021 is expected to increase, which will lead to revenue growth. At the same time, with the emergence of new CDK4/6 inhibitors and generic drugs in the Chinese market, the price of Palbociclib may continue to fall. The price reduction will make Palbociclib more affordable for patients, thus further opening up the market.

Topics Covered:
-The impact of COVID-19 on China’s Palbociclib market
– Sales value of China’s Palbociclib 2016-2020
– Competitive landscape of China’s Palbociclib market
– Prices of Palbociclib in China
– Prices of Palbociclib in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Palbociclib market
– Prospect of China’s Palbociclib market from 2021 to 2025

The post Investigation Report on China’s Palbociclib Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of Salmeterol/Ticasone have had an increasing trend in the Chinese market from 2016 to 2019.The sales revenue in 2020 was approximately CNY296.77million. However, the sales of Salmeterol/Ticasone in 2020 decreased by 21.59% compared with that in 2019 due to the COVID-19 epidemic. The CAGR for Salmeterol/Ticasone is approximately -3.82% from 2016 to 2020.

According to CRI analysis, from 2021 to 2025, the sales of Salmeterol/Ticasone in China will have a recovery growth with the improvement of the epidemic situation and normal operation of overall diagnosis and treatment in hospitals. After the patent for Salmeterol/Ticasone expired, more biosimilar drugs will appear in the market. In China, Respirent Pharmaceuticals Co. Ltd has already submitted an application for Salmeterol/Ticasone in 2021. Therefore, in the next few years, the market share for Glaxo Wellcome (formerly the wellcome Foundation) and GlaxoSmithKline (France) will gradually shrink. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of Salmeterol/Ticasone.

Topics Covered:
-The impact of COVID-19 on China’s Salmeterol/Ticasone market
– Sales value of China’s Salmeterol/Ticasone 2016-2020
– Competitive landscape of China’s Salmeterol/Ticasone market
– Prices of Salmeterol/Ticasone in China
– Prices of Salmeterol/Ticasone in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Salmeterol/Ticasone market
– Prospect of China’s Salmeterol/Ticasone market from 2021 to 2025

The post Investigation Report on Chinese Salmeterol/Ticasone Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY2 million, and its annual sales volume reached 1,745 doses. Therefore, the development prospects are quite good.

According to CRI analysis, from 2021 to 2025, as Shingles Vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement velocity. Therefore, as the market share of Shingles Vaccine will gradually increase, and sales and sales volume will also increase.

Topics Covered:
-The impact of COVID-19 on China’s Shingles Vaccine market
– Sales value of China’s Shingles Vaccine 2016-2020
– Competitive landscape of China’s Shingles Vaccine market
– Prices of Shingles Vaccine in China
– Prices of Shingles Vaccine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Shingles Vaccine market
– Prospect of China’s Shingles Vaccine market from 2021 to 2025

The post Investigation Report on China’s Shingles Vaccine Market 2021-2025 first appeared on CRI Report.

The funeral and interment industry can be divided into four parts from the perspective of service content: funeral services, disposal of remains, cemetery services, and other funeral product sales and services. Among them, funeral services and the disposal of remains are mainly under control of the government agencies, and cemetery services and other funeral products sales and services are mainly provided by private companies.

As of 2019, China has a total of 4,060 funeral service agencies, including 890 funeral management agencies, 1,677 funeral homes, 1431 cemeteries, and 62 other funeral service agencies. By 2020, there will be several listed funeral service companies in China, among which Fushou Garden is the largest.

According to CRI’s research, the funeral and interment market size has showed an upside trend from 2015 to 2020 as the number of deaths and elderly population in China have grown year by year. The funeral and interment market size rose rapidly in 2016, mainly due to the increase in sales caused by price increases.

In 2017, the market size of the funeral and interment also declined after the price was adjusted under the guidance of the government. The number of deaths in China in 2020 increased by 46.39% from 9.98 million in 2019 to 14.61 million in 2020. Therefore, the market scale of the funeral and interment industry expanded the fastest in 2020, from CNY305.5 billion in 2019 to CNY641.2 billion in 2020, with an annual growth rate of 109.85%. The market size of the funeral and interment industry has a CAGR of 25.77% from 2015 to 2020.

CRI predicts that the funeral and interment market will have an increasing trend from 2021 to 2025, as the population ageing continues to rise. The results of the seventh census showed that the Chinese total population stood at 1,41.78 million in 2020. The number of people aged 60 and above was 264.02 million, accounting for 18.70% of the total population.

From 2016 to 2020, the elderly population has shown an increasing trend, with a CAGR of 3.39%. Based on this, it can be predicted that the elderly population will continue to increase from 2021 to 2025. Since the elderly have a greater impact on the number of deaths than other age groups, the size of the funeral and interment market will expand with the increase of the elderly population. In addition, China’s funeral service industry policy encourages the participation of private enterprises and other social forces.

By 2020, the number of registered funeral service companies in China has reached 14,191. In the future, more companies will join the funeral service industry. Therefore, the sales and sales volume of funeral services will increase from 2021 to 2025.

Topics Covered:
-The impact of COVID-19 on China’s Funeral market
– Sales value of China’s Funeral Service 2016-2020
– Competitive landscape of China’s Funeral market
– Prices of Funeral in China
– Analysis on factors affecting the development of China’s Funeral market
– Prospect of China’s Funeral market from 2021 to 2025

The post Investigation Report on China’s Funeral Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, after Ustekinumab entered the Chinese market, the sales increased from CNY0.6 million in 2019 to CNY 2.25 million in 2020. The annual growth rate is 274%

CRI analyzes that the sales of Ustekinumab will continue to increase in the next five years due to market expansion. After Ustekinumab was approved for its first indication in China in 2017, its second indication was approved in March 2020, which is used to treat moderate to severe active Crohn’s disease. With the approval of the new indication, sales will increase accordingly. Besides, Ustekinumab had four approved indications globally, which means the number of approved indications has the potential to expand in China, so the sales will keep increasing. On the other hand, the relatively high price for Ustekinumab results in suboptimal sales in China. Since Ustekinumab has only been in the Chinese market for a short period, Janssen is not enthusiastic about the national medical insurance negotiation. However, with the emergence of domestic biosimilar drugs in the future, the price for Ustekinumab is expected to decrease and the market will be further expanded.

Topics Covered:
-The impact of COVID-19 on China’s Ustekinumab market
– Sales value and volume of China’s Ustekinumab 2016-2020
– Competitive landscape of China’s Ustekinumab market
– Prices of Ustekinumab in China
– Prices of Ustekinumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Ustekinumab market
– Prospect of China’s Ustekinumab market from 2021 to 2025

The post Investigation Report on China’s Ustekinumab Market 2021-2025 first appeared on CRI Report.

By the end of 2020, global cobalt reserves totaled about 7 million tons, 3.60 million tons or 50% of which were in Congo (Kinshasa). Australia, Cuba. Etc. accounted for 5% to 20% respectively while China only accounted for only about 1%.

In 2020, the global production volume of cobalt was about 140,000 tons, decreasing by nearly 3% YOY. The production volume of cobalt in Congo (Kinshasa) was about 95,000 tons, decreasing by nearly 5% YOY. Cobalt production declined consecutively in Congo (Kinshasa) from 2018 to 2020 because Luoyang Molybdenum’ TFM copper and cobalt mine, the world’s third largest cobalt mine, has reduced its production from 2019. Glencore’ Mutanda, the world’s largest mine, has been shut down for technical reforms for three consecutive years since 2020. At the same time, the new crown epidemic has affected the cobalt mining industry, resulting in insufficient cobalt supply,stimulating the rise of cobalt prices.

In recent years, global cobalt production stay above 130,000 tons per year and cobalt demand is also small. Therefore, cobalt prices can be easily manipulated to soar or slump, which is different from copper, aluminum, lead, zinc and other bulk commodities.

According to CRI’ market research, cobalt is mostly used in battery materials. It is estimated that in 2020, more than 60% of global cobalt consumption was attributable to the materials for 3C batteries, energy storage batteries, power batteries for new energy vehicles and other batteries. With the advent of 5G smart phones, 3C electronic shipments and unit charge will increase in the future. Mobile phones and new energy vehicles will account for about 70% of China’s cobalt applications.

If there is no major technological innovation, the cobalt demand from cemented carbides, high-temperature alloys and magnetic materials will remain stable in the next few years. And battery materials will be the largest growth driver for the cobalt demand from 2021 to 2025.

It is expected that li-ion batteries for electric vehicles will be the largest growth area for cobalt consumption in the battery sector. In recent years, the global production volume of electric vehicles has been growing fast at a growth rate far exceeding that of traditional vehicles. In 2020, the production volume of electric vehicles in China reached about 1.456 million units, increasing by 22% as compared to 2019. The demand for cobalt, an important raw material for electric vehicle batteries, will continue to grow. Power batteries have taken up the largest proportion of the downstream applications of cobalt.

As global new energy vehicle industry is developing rapidly, the global cobalt demand will also continue to rise. It is expected that from 2021 to 2025, the global production volume of new energy vehicles will grow at a CAGR of around 40%, the cobalt demand from ternary materials will grow at a CAGR of about 50% and the demand for energy storage lithium batteries will grow at a CAGR of nearly 50%. Meanwhile, ternary batteries will see an increase in penetration rate and their demand for cobalt will grow at a CAGR of 80%. The cobalt demand from 3C batteries and industrial batteries will maintain a CAGR of about 5%. Overall, the CAGR of global cobalt demand will stay around 10% from 2021 to 2025.

Topics covered:
Development environment for the cobalt industry
Supply of and demand for cobalt on global and Chinese markets
Analysis on major downstream industries of cobalt
Price trend of cobalt
Major cobalt mining and smelting enterprises and downstream enterprises in China and the world
Driving forces and market opportunities for the cobalt industry from 2021 to 2025
Threats and challenges to the cobalt industry from 2021 to 2025
Prospect of global and China’s cobalt industries from 2021 to 2025

The post Investigation Report on the Chinese Cobalt Market 2021-2025 first appeared on CRI Report.

According to CRI’s analysis, driven by low mining costs and low environmental protection costs, in the 1990s, Chinese enterprises started mining and exporting rare earth on a large scale. In the past decade, China’s rare earth reserves fell sharply. Its proportion in the global rare earth reserves once exceeded 70% while at the end of 2020, the proportion was only 38%. From 1998 to 2015, the Chinese government introduced an export quota licensing system for rare earth. On Mar. 26, 2014, the WTO ruled that China’s administrative measures for rare earth exports breached WTO rules. On May 1, 2015, the Chinese government canceled its tariffs on rare earth exports. On Jan. 1, 2016, it abolished the export quota licensing system. Before the export quota licensing system was abolished, many Chinese rare earth enterprises had difficulty obtaining export quotas, and smuggling became the main export method. Although the Chinese government rectified this phenomenon many times, it has not been able to completely eliminate this phenomenon.

In China, there is also a total control index system for rare earth ore (rare earth oxide REO) mining. The Rare Earth Mining Index is an enterprise mining index promulgated by the State Council of China, targeting strategic metal resources such as rare earth, tungsten, and molybdenum. In 2020, China’s total control indicators for the mining, smelting and separation of rare earth ore (rare earth oxide REO) are 140,000 tons and 135,000 tons respectively. Compared with 2019, mineral products increased by 6.1%, and smelting and separated products increased by 6.3% in 2020.

According to CRI’s analysis, the mining and refining of rare earth in China is monopolized by six major state-owned enterprises (SOEs). Non-SOEs only have access to downstream industries such as the production and application of rare earth materials.
At present, the annual production capacity of rare earth separation enterprises in China is about 400,000 tons, and the global annual demand is about 200,000 tons. The international market demand is about 90,000-100,000 tons, and the domestic market demand is about 100,000 tons. China’s rare earth dominance in the global market still exists, but its dominant advantage is gradually weakening. With the increase in local mining efforts in the United States, Japan, Australia and other countries, China’s rare earth production has fallen from 81.4% in 2016 to 58.3% to 2020. In 2020, China’s actual production of rare earths will exceed 150,000 tons, which is higher than the quota. The reason is that there are illegal mining and smuggling. There is no tax to engage in illegal mining and smuggling of rare earths, and the profit rate is very high, so it cannot be completely eliminated.

CRI shows that the prices of rare earth oxides and metals in China in 2020 are mostly higher than that in 2019. With the continuous escalation of the Chinese government’s crackdown on the illegal mining of rare earths and the adoption of policies such as the national reserve of rare earths, it is expected that rare earth prices can increase in the next few years.

The downstream demand for rare earths is divided into five major sectors: permanent magnet materials, catalytic materials, luminescent materials, polishing materials, and hydrogen storage materials. With the rapid development of global high-tech industries, rare earths are being applied to more high-tech fields and the consumption of rare earth new materials is growing rapidly. The new energy vehicle industry, the wind power industry and other consumers of rare earth all have a promising future, which promotes the development of the rare earth industry. For example, in 2020, the global production of new energy vehicles reached 2.55 million, among which 1.366 million units were produced in China, up by about 10% YOY. Rare earth hydrogen storage alloys are mainly used in NiMH power batteries. 95% of the world’s rare earth hydrogen storage alloys are supplied by China and Japan. The production of China’s hydrogen storage alloys exceeds 70% of the world’s total production. A hybrid electric vehicle needs about 10 kg of hydrogen storage alloy. In general, a hydrogen storage alloy contains 30% mischmetal, which means that a hybrid electric vehicle consumes about 3 kg of rare earth. The drive motor of a hybrid electric vehicle consumes about 1 kg to 3 kg of neodymium-iron-boron magnetic materials; the drive motor of a battery electric vehicle consumes about 5 kg to 10 kg.

CRI analyzes that according to the plan of the Chinese government, the annual production of new energy vehicles in China will exceed 5 million units by 2025. If this goal can be achieved, new energy vehicles will consume 50,000 tons of rare earths in 2025 or more, which will boost the development of China’s rare earth industry.

Topics Covered:

-Global supply of and demand for rare earth
-Global trade of rare earth
-Chinese government’s policies on rare earth
-Rare earth production in China
-Demand for rare earth in China
-China’s rare earth imports and exports
-Price trends of rare earth and rare earth materials in China
-Major rare earth mining and refining enterprises in China
-Major producers of rare earth materials in China
-Driving forces and market opportunities for China’s rare earth industry from 2021 to 2025
-Forecast on the supply of and demand for rare earth in China from 2021 to 2025

The post Investigation Report on the Chinese Rare Earth Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the development cycle of the construction machinery industry is basically consistent with the macroeconomic development trend. The prosperity of China’s construction machinery is affected by many factors such as the domestic market demand, exports and government policies, which in general are supportive.

The demand in the Chinese construction and machinery market is oriented by investments in fixed assets like the real estate and infrastructure. In general, when China’s real estate and infrastructure investment increases, the demand for construction machinery will follow the step. Fixed asset investment demand is the main factor affecting the development of the domestic construction machinery industry. By 2020, infrastructure accounted for the largest proportion of construction machinery demand (about 45%), and mining and real estate took up about 20% respectively.

CRI’s market research shows that China’s whole set of construction machinery products are mainly exported to countries and regions including the United States, Russia, Japan, Australia, India, and Vietnam, while the machinery parts are mainly exported to the United States Europe and European countries. In 2017, the export value reached USD 20.969 billion, with a reduction of 13.6% YOY. The main reason for this reduction is the target market was greatly affected by the outbreak of COVID-19. In 2020, China’s construction machinery exports to major export target countries fell by about 8.6% YOY. Exports to countries along the “Belt and Road” were US$8.973 billion, accounting for 42.8% of total exports. The decline rate of exports is 16.8%, which was higher than the decline of total exports. Exports to the BRICS countries amounted to US$2.511 billion, accounting for 12%, with a year-on-year decrease of 9.29%. Among them, the Brazilian market share showed a rare increase, with a growth rate of 0.1%.

According to CRI’s analysis, with the improving strength of China’s construction machinery manufacturing, many Chinese companies have entered the international market through mergers and acquisitions, which enables them to make use of the brand, technology and sales channels of the acquired targets so as to make inroads into the global arena

By 2020, the urbanization level in China was about 63.9%, which was above the middle level in the world, far lagging behind that of developed countries. During 2018-2022, the urbanization rate is expected to reach 65.5%, namely, an increment of more than 80 million urban population. The rise of urbanization will promote the development of the real estate and infrastructure construction, and further drive the demand for construction machines. In addition, the Report on Digital Development in Rural China 2020 pointed out that rural areas in China will continue to develop during the 14th Five-Year Plan period (2021-2025). Therefore, the modernization of rural infrastructure and other modernization will promote the demand for construction machinery in China. At the same time, with the alleviation of the new crown epidemic, overseas sales of Chinese construction machinery will have a recovery growth, and export value may see great growth. Overall, from 2021 to 2025, the construction machinery industry in China will continue to develop.

main content:
-Government policies of China’s construction machinery industry
-Supply and demand of China’s construction machinery industry
-Analysis on the import and export of China’s construction machinery industry
-Major construction machinery manufacturers in the Chinese market
– Competition landscape of China’s construction machinery
-The driving forces and market opportunities of China’s construction machinery industry, 2021-2025
-Threats and challenges by China’s construction machinery industry, 2021-2025
-Prospects for China’s construction machinery industry, 2021-2025

The post Investigation Report on the Chinese Construction Machinery Industry Market 2021-2025 first appeared on CRI Report.